.jpg)
Listen: Moderna’s setback, the saga of drug pricing reform & a CEO’s next act
Is drug pricing reform actually happening? Why was Moderna’s stock down? And what’s next for Alnylam’s CEO?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to step down as CEO of Alnylam Pharmaceuticals after almost 20 years with the company. We also discuss the latest news in biotech, including the Covid-19 vaccine for kids and Moderna’s disappointing earnings call.
